Vero Combines Stanford's Proteomic Organ and Cell Aging Technologies to Build a New Clinical and Consumer Tool for Predictive Health

Vero Combines Stanford's Proteomic Organ and Cell Aging Technologies to Build a New Clinical and Consumer Tool for Predictive Health

Higher-resolution biological aging insights predict disease earlier and guide more targeted interventions

Vero Combines Stanford’s Proteomic Organ and Cell Aging Technologies to Build a New Clinical and Consumer Tool for Predictive Health

Higher-resolution biological aging insights predict disease earlier and guide more targeted interventionsCORTE MADERA, Calif.--(BUSINESS WIRE)--Vero, a predictive health company on a mission to end age-related chronic disease, today announced it is ad... L'articolo Vero Combines Stanford’s Proteomic Organ and Cell Aging Technologies to Build a New Clinical and Consumer Tool for Predictive Health è un contenuto originale di 01net.